The field of cell, gene and tissue therapies, now known as regenerative medicine, has seen tremendous and sustained growth in discovery and early-stage development in recent years, but the pipeline of late-stage candidates for commercialization has had trouble keeping pace – a circumstance that looks to be changing, helped by the US FDA’s efforts to establish a regulatory framework and the incentives of expedited review programs.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?